Generic Prilosec
This article was originally published in The Tan Sheet
Executive Summary
Genpharm will receive up to 15% of Andrx' profits from generic omeprazole under agreement settling a dispute over which firm was first to file an ANDA for AstraZeneca's Rx proton pump inhibitor. Andrx will market generic omeprazole either under its own or Genpharm's application, depending on which more quickly can be brought to market. Omeprazole loses exclusivity in October 2001 assuming AstraZeneca receives six months of pediatric exclusivity. AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC was the subject of an Oct. 20 NDAC meeting (1"The Tan Sheet" Oct. 23, 2000, p. 3)